The hypoventilation management market is projected to experience substantial growth in the coming years, with a valuation expected to reach USD 7.1 billion in 2023. According to recent analysis, the market is anticipated to expand at a compound annual growth rate (CAGR) of 5.3%, ultimately reaching USD 11.9 billion by 2033.
This growth is primarily driven by the increasing prevalence of respiratory conditions that lead to hypoventilation, coupled with the rising awareness of the importance of effective respiratory management in clinical settings. As healthcare providers continue to prioritize patient safety and improved respiratory outcomes, the demand for innovative hypoventilation management solutions is expected to rise.
The global hypoventilation management market’s robust trajectory underscores the critical need for advancements in respiratory care technologies and management strategies, positioning it as a key area of focus for healthcare professionals and organizations worldwide.
Growing healthcare expenditure, advancement in the treatment options, unhealthy lifestyle, rising incidence of obesity, growing initiatives by government and private organisations to spread awareness towards health and lack of exercise in the daily routine are the factors that will expand hypoventilation syndrome treatment market.
Also, increase in the research and development activities and ongoing clinical trials will provide beneficial opportunities for hypoventilation syndrome treatment market in the forecast period of 2023-2033.
Market Competition
The global Hypoventilation management market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc, Strides Pharma Science Limited, X Gen Pharmaceuticals Inc, ResMed, Koninklijke Philips NV, Hikma Pharmaceuticals, Lincare Holdings
Some recent developments in this industry are:
- In June 2022, Verona Pharma, a pharmaceutical company, announced the completion of the patient enrolment, with more than 800 subjects involved for its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease, a type of hypoventilation disorder. It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year 2022 and further data from ENHANCE-2 in the third quarter of 2022.
- In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for US$ 270 Million. These products are indicated for the treatment of various types of hypoventilation disorders.
- In May 2022, Alembic Pharmaceuticals Ltd, a pharmaceutical company, received final approval from the USA health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the USA Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.
Key Companies Profiled
- Accord Healthcare Limited
- Avet Pharmaceuticals Inc.
- Nostrum Laboratories Inc.
- Lannett Co Inc.
- Strides Pharma Science Limited
- X Gen Pharmaceuticals Inc.
- ResMed
- Koninklijke Philips NV
- Hikma Pharmaceuticals
- Lincare Holdings
Key Segments Profiled in the Hypoventilation Management Market Industry
By Disease Type:
- Chronic Obstructive Pulmonary Disease
- Obesity Hypoventilation Syndrome (OHS)
- Central Alveolar Hypoventilation
- Neuromuscular Disorders
By Treatment Type:
- Oxygen Therapy
- Non-Invasive Mechanical Ventilation
- Drug Therapy
By End User:
- Hospitals
- Specialty clinics
- Home care
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
